AKT1 and glioblastoma: Wnt/β-catenin, MAPK/ERK, PI3K/AKT and STAT3 signaling are highly activated in glioma, so it is conceivable that simultaneous pharmacological inhibition of all these signaling pathways might be the most effective therapeutic strategy for the prevention and treatment of glioblastoma.